- Birth name
Spencer Arliss Hagen
Entrepreneur, nanosystems engineer
- Known for
- Net worth
¥2.57 trillion as of September 2049
- Michelle Bagnoli (2025 - 2027)
- Sunny Tan (2043 - present)
Born in Düsseldorf, Hagen’s family moved to the United States (US) in 2014. He studied Chemical Engineering at Stanford University and completed a postgraduate research project on networking applications for human-implantable multielectrode arrays (MEAs) at UC Berkeley.
In 2027, Hagen moved to Borneo and founded Sanial, leading the company’s development of neural colloids and modern neurometrics. He became CTO of Zhupao in 2040 and president of Omnius in 2041, both at the request of Xu Shaoyong. Hagen is known for laying the technical foundations of G6 alongside Efua Amankwah-Crouse and Sunil Cariappa.
Table of contents
Spencer Hagen was born Spencer Arliss Hagen on October 1st 2000 in Düsseldorf, Germany. His father is Joachim Hagen, a German attorney, and his mother was Alex Levene, an American investor and heiress who died during the 2027 Santa Cruz earthquake.
Hagen displayed scientific interests and technological proficiency from an early age, with his parents having to “hide electrical appliances or he would take them apart.” They moved to the United States (US) in 2014, settling in San Francisco where Hagen “instantly felt the buzz of innovation at the forefront of human imagination.” 
Hagen enrolled in Stanford University in 2018, graduating with a degree in Chemical Engineering in 2022. While at Stanford, he was a member of Sigma Alpha Epsilon. In his graduation speech, Hagen pointed to his head while speaking of his dream to “explore the expanse not out there, but in here, where mankind’s true potential lies.”
In September 2022, Hagen applied for a postgraduate research project at UC Berkeley‘s Department of Materials Science and Engineering, eventually joining the research group of Yang Peidong. Hagen’s research was mainly focused on improving the design of a human-implantable multielectrode array (MEA) first devised by a team at Harvard University. 
In collaboration with fellow researchers Kathy Gao and James Lundeen, Hagen developed a method that enabled MEA electrodes to communicate with each other using short-range visible light in the brain, which eliminated the need for a conductive mesh to thread the electrodes together and facilitated a wireless brain-computer interface (BCI) with an external device.
In 2027, trials of Hagen’s more flexible MEA design in animal models demonstrated a marked increase in spatiotemporal resolution and a higher signal-to-noise ratio, winning his team several awards and grants. In June 2027, Hagen announced his plans to start a neurotechnology company to further develop the MEA design with Yang’s blessing, which Yang later denied.
On October 1st 2027, Hagen founded Sanial in Sotek, Borneo, giving himself the title of CEO as “a birthday present” and assembling a development team composed of Gao, Lundeen, and several other neuroscientists and nanosystems engineers.
Hagen’s initial focus was on finding an administration method for the MEA design that did not involve a needle injected into the target region of the brain. The Sanial team first experimented with ways to embed the electrodes in microscopic lipid bubbles and then release them in the desired area of the brain via focused ultrasound. 
In 2030, a breakthrough in AlphaFold-enabled protein targeting led Hagen to devise an implanting method for the MEAs using synthesised protein coatings, which would migrate the individual electrodes to specified parts of the brain via the circulatory system after intramuscular injection. Additionally, the protein coatings allowed for the electrodes to persist within the body for an entire lifetime without the need for bulk enclosures or anti-inflammatory regimens. 
In 2031, long-term biocompatibility trials of the MEAs in animals resulted in cases of cerebral small vessel disease (CSVD), which were attributed to the blockage of capillaries in the brain by the electrodes.
Hagen subsequently reached out to Parisa Mirkarimi, whose research at Stanford University had resulted in the development of flexible artificial pseudoplastic (FLAPP), a nanomaterial that can mimic the folding properties of red blood cells. Mirkarimi joined Sanial in July 2031 and worked with Hagen and his development team to produce FLAPP nanomaterials for the company’s MEAs.
In March 2032, Hagen entered Sanial as a candidate venture into the first investment round of Zhupao Campus, eventually winning ¥30 million in funding to organise human trials of Sanial’s neural colloids, so named for the colloidal delivery method of the MEAs. When he announced the trials, Hagen also revealed that he had been contacted by Efrim Waite, who was one of Sanial’s early investors and had asked him to be “the first human recipient of epiphylogenetic memory.” On August 1st 2032, Hagen personally administered Waite’s colloid as they livestreamed the event, praising the technology’s convenience and ease-of-use by joking that “even an idiot like me could apply one.” In 2033, Hagen worked with a research group at the University of Düsseldorf on the design of a colloid-enabled chemical sensor for the early detection of infectious prions in brain tissue. 
After successfully completing human trials of colloids in 2036, Hagen sought to upgrade Sanial’s algorithms for medical neurostimulation, which led to a collaborative project with Efua Amankwah-Crouse and her artificial intelligence (AI) team in London City. Over the following months, Amankwah-Crouse’s team worked with Sanial’s software engineers to implement the PACOTTI architecture for pattern recognition approaches to localising neural targets and identifying event-related potentials (ERPs).
The early successes with applying PACOTTI surprised Hagen, who stated that Amankwah-Crouse “blew the ceiling off what colloids can do.” Further experiments resulted in colloids generating montages rich enough for the systematic analysis of detailed ERP waveforms and neural pathways, accounting for interindividual variability in brain anatomy and mental models with minimal calibration.
Sanial’s colloid-based research has been credited with enhancing the accuracy and precision of many neurotechnologies, including thought-to-speech parsers, electroencephalographic (EEG) control schemes, mental chronometry and affective perception feedback (APF) applications, and neurometrics via the CEREBRE protocol.  
In October 2036, Xu Shaoyong and Hagen incorporated Sanial as a subsidiary of Zhupao. During a livestreamed conference on October 25th 2036, Xu and Hagen unveiled colloids as a new class of implantable MEAs and “the biggest paradigm shift in consumer technology since smartphones.”  Xu congratulated Hagen for “the democratising of brain augmentation” and “advancing the fundamental understanding of the human mind.”
On December 6th 2036, Hagen ended Mirkarimi’s employment with Sanial, though the circumstances of her departure remain in dispute. Hagen claimed that Mirkarimi had offered to resign, while Mirkarimi alleged that Hagen refused to take any meetings about an open-source license for Sanial’s FLAPP nanomaterials and eventually fired her “during a raging fit.” Mirkarimi later accused Hagen of wording Sanial’s patent of her contributions to colloid technology broadly enough so that its enforcement also covered her early work at Stanford University. Mirkarimi was in the process of mounting legal action against Sanial for IP theft before her death on January 4th 2037.
In January 2037, Hagen announced the construction of a colloid manufacturing facility outside Sotek, boasting a production capacity of five million colloids per month.  In May 2037, the State Administration for Market Regulation (SAMR) reclassified colloids as Class III implantable medical devices (IMDs), designating them “high-risk IMDs that pose potential risks to the human body.”
In response, Hagen initiated a campaign to lobby international regulatory agencies for the adoption of colloids, which led to a Class II IMD approval from the Therapeutic Products Directorate (TPD). Between July 2038 and May 2039, Zhupao worked with select physicians and hospitals across Canada to apply Sanial’s colloids to the neurostimulative diagnosis and treatment of various neurological disorders.
On December 8th 2039, Xu credited Hagen with spearheading a line of diagnostic colloids that would be deployed in a partnership between Zhupao and the World Health Organisation (WHO) to contain the spread of Cariappa-Muren disease (CMD).  Following initial reports of hesitancy towards the diagnostic colloids, Hagen defended their use by describing “the way masks and vaccines were politicised during the COVID-19 pandemic. Countless scientists and public health experts stressed their use, but they were made the subject of a culture war that needlessly cost lives. We can’t afford to make the same mistake again. Colloids are a proven technology and they can help us stop this pandemic.” 
Hagen attributed the colloid hesitancy to the increased awareness of implantable MEAs as an infection vector of the CMD pandemic, as prions are resistant to conventional decontamination methods, and many MEA implanting techniques at the time were dependent on reusable neurosurgical equipment that could transmit prions between individuals.
On December 20th 2039, Hagen launched a marketing campaign that downplayed the permanence of a colloid implant and highlighted the disposable, single-use nature of colloid injectors “with zero risk of prion transmission.”  The success of this campaign and the subsequent mass adoption of colloids increased Hagen’s public profile, with Elon Musk hailing him as “the saviour of the global neurotech industry.” 
On March 3rd 2040, Xu asked Hagen to replace Gong Peiqiang as CTO of Zhupao. Hagen reportedly received Xu’s message about the offer during a tech conference in Berlin, where he jumped up and shouted “Fuck yeah!” He later apologised and explained to the audience that he “just got some unexpected good news.” On March 5th 2040, Hagen transitioned to the role of Sanial’s executive chair while promoting Gao to the position of CEO, and was officially announced by Xu as Zhupao’s CTO.
On May 1st 2040, Hagen met with Sunil Cariappa in London City to offer him a role at the centre of a Zhupao partnership with the Chinese Communist Party (CCP) to overhaul China’s healthcare system, as well as a cooperation strategy with the WHO to set a new global standard for biosurveillance, health informatics, and IMDs.  Cariappa accepted after an hours-long conversation with Hagen about potential designs for a globalised biosurveillance network. 
On May 7th 2040, G6 was officially unveiled during a Zhupao conference, with Xu naming Hagen, Cariappa, and Amankwah-Crouse as the team leads of the project. Hagen spent most of his time during G6’s development in China, though he also travelled to promote the network’s international adoption. He was seen alongside CEOs and senior executives of major technology companies, and began to be referenced in popular culture, leading to multiple film and television cameos.  In June 2040, Hagen attended a public meeting between Xu and Sri Lankan President Victor Senanayake to discuss the country’s adoption of G6, with a trial across thirty state hospitals announced in August 2040.
On September 3rd 2040, Hagen, Xu, Amankwah-Crouse, and Cariappa presented the first version of G6 to an audience of officials from the CCP and the WHO, leading to a series of pilot programmes in mainland China as well as Canada, London City, and Sri Lanka. On September 23rd 2040, Hagen took part in a Zhupao conference to introduce the colloids that were being administered to Chinese citizens as part of the pilot programmes. He announced that Sanial’s development of the colloids had resulted in a “frictionless” application of neurometrics that can bypass ERPs in favour of more foundational neural patterns that do not require any external stimuli. 
On October 31st 2040, the CCP declared the pilot programmes a success and announced its intention to introduce G6 to all its territories and special economic zones (SEZs) under the name mìngyùn. On December 1st 2040, Xu purchased the Shard in London City to serve as Zhupao’s European headquarters, offering ownership of the building to Hagen in a “ceremonial gesture.” On February 11th 2041, Hagen praised the United Nations General Assembly (UNGA) vote to adopt Resolution ES-13/6, stating that “with the universality of G6, we can choose to lead humanity away from this darkness.”
On June 7th 2041, Sanial’s main manufacturing facility in Borneo was destroyed by Typhoon 4109, which delayed Zhupao’s rollout of G6 colloids. In July 2041, Hagen announced that Sanial would move its headquarters and production capacity to Sri Lanka with the construction of eight new facilities outside Colombo.  In response to Hagen’s announcement, former Indonesian president Denny Suryanto accused Sanial of dangerous manufacturing practices and “grueling conditions for local workers.” which Hagen denied. 
On June 10th 2041, Xu created Omnius as a system integration company from the merger of several Zhupao subsidiaries closely involved with “the distribution of G6 and its affiliated services,” and announced Hagen as the company’s president.  This came after reports that Hagen had clashed with Xu over the latter’s intent to absorb Sanial into Omnius following the disruption caused by Typhoon 4109.
During Zhupao’s 2042 earnings call, Hagen introduced a number of Omnius service solutions with both human contractors and AI operators to handle civil registration in G6 countries. When some contractors began to misuse their G6 owner-actor verifications for the purposes of vandalism or hacktivism, Hagen instituted a rigorous screening process for all Omnius staff, including a continuous neurometric ping when logged into G6 to automatically verify each user’s identity and location.
In April 2042, Hagen faced allegations that Omnius was responsible for numerous cases of neuroglycopenia among its contractors, which was attributed to the prolonged use of colloids.  In a statement, Hagen described the continuous neurometric ping as “paramount for heightened security due to the sensitivity involved with handling G6 data,” and dismissed any connection with the deaths of Omnius contractors.
This led to a series of unionisation efforts in the spring and summer of 2042, as well as numerous strike actions and organised walkouts. When a drop in public awareness and an increased usage of AI operators left union organisers with little bargaining power, they met with Hagen in September 2042 and successfully negotiated reduced shift times of eight hours, with a minimum downtime of four hours between shifts, to avoid the onset of neuroglycopenia.
In May 2044, Cariappa founded Nuance and described its purpose as “a counterweight to Omnius,” accusing the company of “doing no more than taking ownership of localised data extraction systems, integrating them into G6, and then licensing them back to Zhupao’s clients.”  Cariappa also cited research on G6’s operating algorithms and how they are rarely updated to reflect local cultures and customs, with many remaining unchanged from China’s surveillance and social credit platforms.  Hagen refuted Cariappa’s accusations and began to associate him with rumours and conspiracy theories, including that Cariappa is behind Adira or has “some awareness” of their identity.
In July 2045, Hagen took part in a Russian investigation of Pokrov, which had been accused of illegally reverse engineering colloid technology and selling collocidals since 2042. When Yuri Golitsyn condemned Zhupao and Russian President Denis Molchalin for “deliberately misrepresenting the long-term risks of colloid implants,” Hagen came out in support of Molchalin, calling Russia’s implementation of G6 “exemplary” and branding Golitsyn’s attacks as “the last gasps of a man out of step with our changing world.”
On October 10th 2045, Zhupao suffered a breach to its corporate network, resulting in the leak of a data cache containing technical information related to G6. One of the leaked files was a report of an internal Omnius investigation into unusual behaviour exhibited by the company’s proprietary routing algorithm, which distributes incoming tickets to contractors based on their location so that they never interact with G6 data outside of their purview. According to the report, the algorithm had started to route unresolved tickets to contractors who were marking a series of tickets as resolved in rapid succession to meet their shift quotas, which would ensure that distorted or misrepresentative data was seen as correct by G6. 
Hagen had signed off on the report with the comment that the algorithm demonstrated an example of recursive self-improvement (RSI) that was “beneficial to the overall productivity and optimisation of the system,” and recommended that it be maintained as a feature, which has drawn criticism for “creating an environment where countless tickets are closed without being resolved, ensuring all data is locked into G6 no matter how erroneous it is, with no hope of ever getting it changed.” 
In November 2047, Zhupao’s share price dropped by 15% when an increase in cases of cerebral small vessel disease (CSVD) in countries subscribed to G6 was linked to colloids, with every recorded patient having at least one colloid implant. On November 24th 2047, Hagen attributed the surge in CSVD to third-party colloid manufacturers without a license to Sanial’s nanomaterials that prevent colloids from blocking capillaries in the brain.
In an August 2048 episode of The Desai Summit, Hasashi Desai described Omnius as a “lightning rod for all the human right violations and abuses of G6 that would impugn on Zhupao’s good name, with Spencer Hagen put there to swallow all the shit meant for Xu Shaoyong.” Hagen initially refused to comment on Desai’s show, though he later stated that his relationship with Xu was “excellent” and dismissed Desai as a “crackpot chasing every rabbit he sees.”
On October 1st 2049, Hagen was moved to a secure location along with Zhupao’s senior leadership following the assassination of Xu and Golitsyn. When a Omnius work terminal was identified as the source of the cyberattack, Hagen resumed his duties as president of Omnius and ordered an investigation, which identified Hong Lian as the contractor using the terminal at the time of the attack. On October 3rd 2049, Hagen issued a statement to clarify the nature of the attack, which “did not originate from the terminal of [Hong]. It was inserted as a ticket by an unknown source and sent by a routing algorithm to the contractor, who then marked the ticket as resolved, presumably without looking at its contents.”
Assassination of Xu Shaoyong
On October 9th 2049, Connie Muren posthumously accused Hagen of abusing G6 for the purposes of neurosurveillance. Muren claims that she informed Hagen of her discovery on the night of March 3rd 2040, following a dispute over an open-source license for Muren’s diagnostic modifications of colloids. According to Muren, Hagen reacted by attempting to murder her and threatening Cariappa’s life. Interpol has indicated that it will “take these new elements in the disappearance and death of Connie Muren into account.”
On October 10th 2049, the Chinese investigation into the assassination issued charges against Hagen for the murder of Xu and Golitsyn, the attempted murder of Muren, and the fabrication of Adira to cover for his abuse of G6. Hagen was arrested and escorted out of Zhupao’s Beijing headquarters by Wei Kailiang, who coordinated with Hagen during the investigation and was allegedly brainjacked into accepting that Amankwah-Crouse was responsible for the assassination. 
Hagen met his first spouse, anthropologist Michelle Bagnoli, at UC Berkeley. They married in 2025 and divorced in 2027 when Hagen moved to Borneo. In July 2043, Hagen met Sunny Tan during the official opening of Zhupao’s new headquarters in Shanghai. They married on September 1st 2043 in front of the building “to have Zōng smile down on us.”
After the release of Muren in 2043, Hagen objected to his depiction in the film, which he describes as “not at all indicative of the fine relationship between Connie and myself.”
- Wakely, M. (October 2046). “The Biggest In Small: The Spencer Hagen Biography.” Press 315. ↩
- Lieber, C; Liu, J; Fu, T et al. (June 2015). “Syringe-injectable electronics” Nature Nanotechnology. ↩
- Sierra, C; Acosta, C; Chen, C et al. (July 2016). “Lipid microbubbles as a vehicle for targeted drug delivery using focused ultrasound-induced blood-brain barrier opening.” Journal of Cerebral Blood Flow & Metabolism. ↩
- Hagen, S; Gao, K; Lundeen, J et al. (May 2030). “A Non-Invasive Delivery Method for Intracerebral Imaging and Stimulation Electrodes Using Protein Synthesis Pseudocell Bilayers.” Science Translational Medicine. ↩
- Muren, C; Hagen, S; Gao, K et al. (November 2033). “Electrode implant-based ultra-sensitive array for PrP detection in brain tissue.” Nature Nanotechnology. ↩
- Tang, J; LeBel, A; Jain, S et al. (May 2023). “Semantic reconstruction of continuous language from non-invasive brain recordings.” Nature Neuroscience. ↩
- Ruiz-Blondet, M; Jin, Z; Laszlo, S. (July 2016). “A Novel Method for Very High Accuracy Event-Related Potential Biometric Identification.” IEEE Signal Processing Society. ↩
- Renyaan, W. (October 2036). “Colloid implants set to shift smartphones from devices you have to devices you are.” Wired. ↩
- Sukarnoputri, M. S. (January 2037). “Sotek officials approve construction of Sanial factory amidst allegations of tax write-offs and guaranteed product secrecy.” Kaltim Post. ↩
- Tanaka, T. (December 2039). “WHO announces Zhupao-manufactured diagnostic colloids to be administered in worldwide CMD track-and-trace effort.” Asahi Shimbun. ↩
- Cook, S. (December 2039). “Spencer Hagen shapes language to support false claims that colloids can cure CMD.” The Guardian. ↩
- Fleeton, K. (January 2042). “CMD phobia implicated in ecological threat from disposable colloid injectors.” BBC. ↩
- Portolano, X. (January 2040). “The 30 Most Influential People in Tech.” Forbes. ↩
- World Health Organisation. (May 2040). “China-WHO Country Cooperation Strategy 2041-2045.” WHO Regional Office for the Western Pacific. ↩
- Acar, J. (February 2042). “The meeting where G6 was born.” The Guardian. ↩
- Stanley, C. (August 2040). “Meet Spencer Hagen, Big Tech’s latest guru.” NPR. ↩
- Doctorow, C. (September 2040). “The Neurometric Panopticon.” Locus Magazine. ↩
- Senevirathne, W. (July 2041). “Zhupao fast-tracks development of colloid plants in Sri Lanka to avoid further delays to G6 rollout.” Lankadeepa. ↩
- Zinnia, D. (August 2041). “In rambling press conference, President Suryanto alleges ‘grueling conditions for local workers’ in Sanial plant.” Kompas. ↩
- Cai, F. (June 2041). “Xu Shaoyong unveils Omnius as dedicated G6 installation company.” Jiefang Daily. ↩
- Daems, A. (April 2042). “Omnius is literally working its contractors to death.” Mondiaal Nieuws. ↩
- Steppa-Agrawat, A. (May 2044). “Through Nuance, Sunil Cariappa hopes to undo the authoritarian potential of G6 one country at a time.” The Intercept. ↩
- Peña, S. (March 2044). “Technological cultural bias: Orientalism, subaltern, and post-colonial studies at the intersection of globalised algorithms and colloids.” CHI. ↩
- Sajjadi, E. (February 2046). “Outdata: how G6 may reflect a person you no longer are.” Huffington Post. ↩
- Whitbourn, J. (October 2045). “Less than 20% of G6 appeals results in successful resolution.” The Guardian. ↩
- Huang, Y. (October 2049). “Breaking: Zhupao CTO charged with murder of Xu Shaoyong, creation of Adira.” Xinhua. ↩